(Ars Technica) – Personalized mRNA vaccines against melanoma—the deadliest form of skin cancer—reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, pharmaceutical partners Merck and Moderna announced Thursday.

The results are a significant advance in melanoma treatment; Merck and Moderna are already engaging with regulatory authorities to get the vaccine approved. More broadly, the vaccine’s success bolsters hope that mRNA vaccines and individualized cancer-targeting medicines offer a new paradigm for cancer therapies. (Read More)